FDA Safety Warning: Blood Clot Risk with Drospirenone Contraceptives

FDA has issued safty notice for women who are taking drospirenone birth control pills. Keeping latest study results in mind FDA has urged gynecologists and physicians to reckon the risk of Drospirenone while prescribing oral contraceptive pills. FDA has also asked manufacturer of those pills to update drug label.

Oral contraceptive pills that contain Drospirenone have been found to increase blood clotting events. Blood clotting is an essential process in body system. The process helps to heal wounds and stop bleeding by clotting blood at the site of wound.

But, the same process poses threat to life when it occurs in blood carrying veins and capillaries. Unnecessary blood clots in capillaries obstruct blood flow which eventually leads to stroke and heart diseases such as cardiac arrest, heart attack.

Dropirenone is widely used in combination birth control pills. It is synthesized progesterone. Studies, conducted by FDA itself, reported increased risk of blood clotting in people who were taking drospirenone was 3 times greater than those who were taking other contraceptive pills. FDA has revised its drug label and safty information pills that contain drospirenone.